In Brief: Chiron/Ciba
Executive Summary
Chiron/Ciba: Firms enter research collaboration with New York University for NYU's optical DNA mapping technology. Chiron and its 49% shareholder Ciba believe that the optical mapping approach "is dramatically faster than existing methods" and requires only "engineering advances in chamber design, streamlined image analysis and software programming in order to maximize throughput" in order to have commercial application for disease research and other uses. Chiron will have exclusive licensing rights to commercialize the technology. Ciba and Chiron both have other collaborations in the genomics field, with Ciba recently signing a $60 mil. agreement with Myriad and Chiron in the process of acquiring the gene therapy company Viagene ("The Pink Sheet" May 8, T&G-13)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth